CheckMate 214 9-year Update

Endast för hälso- och sjukvårdspersonal

CheckMate 214 9-year Update and Immunotherapy-Related Toxicity Management in Renal Cell Carcinoma (RCC)

A recorded expert lecture by Dr Anna Olsson-Brown focusing on the long‑term follow‑up of patients treated within the CheckMate 214 study, placing the results into a clinical context relevant to everyday practice. (11:24 min)

Key topics include:

Patient selection and mechanism of action in immunotherapy
Overview of the CheckMate 214 study design and long-term follow‑up
Key considerations when interpreting 9‑year data
Reflections on how long‑term outcomes may inform treatment discussions in clinical practice
Safety and toxicity management advice

References:

OPDIVO (nivolumab) SmPC.
Choueiri t. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol. 2026;37(7):960-973. doi:10.1016/j.annonc.2026.02.017.

7356-NOR-2600007 20.06 2026 / video ONC-ND-2600001 27.08.2026